ketamine has been researched along with Anhedonia in 43 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Anhedonia: Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 9.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| "Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions." | 8.31 | Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions. ( Gu, LM; Lan, XF; Ning, YP; Wang, CY; Yang, XH; Zhang, B; Zheng, W; Zhou, YL, 2023) |
| " The sucrose consumption test, forced swim test, open field test, elevated plus maze, and Morris water maze were respectively used to assess anhedonia, behavioral despair, general locomotor activity, anxiety-like behavior and spatial reference memory." | 8.31 | Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress. ( Kingir, E; Sevinc, C; Unal, G, 2023) |
| "This preliminary study found that repeated ketamine infusions appeared to be effective at rapidly ameliorating anhedonia, with similar efficacy in MDD and BD." | 8.12 | Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. ( Gu, LM; Lan, XF; Ning, YP; Sun, CH; Wang, CY; Zhang, B; Zheng, W; Zhou, YL, 2022) |
| "Anhedonia was induced by chronic stress in male mice and assayed by preferences for sucrose and female urine (n = 5-7 mice/group)." | 8.12 | Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit-Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice. ( Georgiou, P; Gould, TD; Rudolph, U; Thompson, SM; Troppoli, TA; Zanos, P, 2022) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 8.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "Although preliminary, present findings suggest that repeated subcutaneous esketamine infusions are effective for the treatment of anhedonia in both unipolar and bipolar depressed patients." | 8.02 | Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. ( Barbosa, MG; Del-Porto, JA; Delfino, RS; Fava, VAR; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sant, LCD; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA, 2021) |
| " Here we aimed to compare the effects of (R)-norketamine ((R)-NK), (S)-NK, (2R,6R)-HNK, and (2S,6S)-HNK in a mouse model of depression induced by chronic corticosterone (CORT) injection." | 7.96 | (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. ( Ago, Y; Chen, L; Hashimoto, H; Hashimoto, K; Higuchi, M; Kasai, A; Naito, M; Nakagawa, S; Nakazawa, T; Seiriki, K; Tanabe, W; Tsukada, S; Yamaguchi, T; Yokoyama, R, 2020) |
| "After adjusting for age, sex, primary diagnosis, concomitant medication, body mass index, and baseline depression severity, there was a statistically significant reduction in symptoms of anhedonia with IV ketamine treatment (F (2, 235." | 7.96 | Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia." | 6.82 | The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. ( Ceban, F; Ho, R; Jasrai, AK; Kim, H; Lui, LMW; McIntyre, RS; Nasri, F; Nogo, D; Rosenblat, JD; Vinberg, M, 2022) |
| "Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists." | 6.80 | Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. ( Lally, N; Luckenbaugh, DA; Niciu, MJ; Nugent, AC; Roiser, JP; Zarate, CA, 2015) |
| "Ketamine is an anaesthetic medication that acts as an antagonist of the NMDA receptor and has antidepressant potential." | 6.61 | Efficacy of Ketamine in bipolar depression: focus on anhedonia. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, Ł; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczk, A, 2019) |
| "Evidence has shown that brain-derived neurotrophic factor (BDNF) is associated with anhedonia symptoms in major depressive disorder (MDD) patients, while the rapid antianhedonic effects of ketamine may occur independently of depressive symptoms." | 5.69 | Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder. ( Gu, L; Lan, X; Li, Z; Ning, Y; Wang, C; Zhang, B; Zheng, W; Zhou, Y, 2023) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 5.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| "This study suggests that ketamine is effective in treatment-resistant bipolar depression and may reduce suicidal ideation and anhedonia." | 4.91 | Efficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis. ( Khosh-Chashm, D; Mascarenhas, SS; Parsaik, AK; Singh, B, 2015) |
| "The NMDA antagonist ketamine demonstrated a fast antidepressant activity in treatment-resistant depression." | 4.31 | Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons. ( Belloch, FB; Cortés-Erice, M; Díaz-Perdigon, T; Herzog, E; Puerta, E; Tordera, RM; Zhang, XM, 2023) |
| "Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions." | 4.31 | Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions. ( Gu, LM; Lan, XF; Ning, YP; Wang, CY; Yang, XH; Zhang, B; Zheng, W; Zhou, YL, 2023) |
| " The sucrose consumption test, forced swim test, open field test, elevated plus maze, and Morris water maze were respectively used to assess anhedonia, behavioral despair, general locomotor activity, anxiety-like behavior and spatial reference memory." | 4.31 | Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress. ( Kingir, E; Sevinc, C; Unal, G, 2023) |
| "This preliminary study found that repeated ketamine infusions appeared to be effective at rapidly ameliorating anhedonia, with similar efficacy in MDD and BD." | 4.12 | Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. ( Gu, LM; Lan, XF; Ning, YP; Sun, CH; Wang, CY; Zhang, B; Zheng, W; Zhou, YL, 2022) |
| "Anhedonia was induced by chronic stress in male mice and assayed by preferences for sucrose and female urine (n = 5-7 mice/group)." | 4.12 | Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit-Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice. ( Georgiou, P; Gould, TD; Rudolph, U; Thompson, SM; Troppoli, TA; Zanos, P, 2022) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 4.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "IV ketamine was effective in reducing symptoms of depression, SI, anxiety, and anhedonia in both cohorts in this large, well-characterized community-based sample of adults with TRD." | 4.12 | Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Shekotikhina, M; Siegel, A; Simonson, K; Subramaniapillai, M, 2022) |
| "Although preliminary, present findings suggest that repeated subcutaneous esketamine infusions are effective for the treatment of anhedonia in both unipolar and bipolar depressed patients." | 4.02 | Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. ( Barbosa, MG; Del-Porto, JA; Delfino, RS; Fava, VAR; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sant, LCD; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA, 2021) |
| " Here we aimed to compare the effects of (R)-norketamine ((R)-NK), (S)-NK, (2R,6R)-HNK, and (2S,6S)-HNK in a mouse model of depression induced by chronic corticosterone (CORT) injection." | 3.96 | (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. ( Ago, Y; Chen, L; Hashimoto, H; Hashimoto, K; Higuchi, M; Kasai, A; Naito, M; Nakagawa, S; Nakazawa, T; Seiriki, K; Tanabe, W; Tsukada, S; Yamaguchi, T; Yokoyama, R, 2020) |
| "After adjusting for age, sex, primary diagnosis, concomitant medication, body mass index, and baseline depression severity, there was a statistically significant reduction in symptoms of anhedonia with IV ketamine treatment (F (2, 235." | 3.96 | Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| " We examined the effects of isolation stress (IS) and the fast-acting antidepressant ketamine on anhedonia and depression-like behavior, spine density, and synaptic proteins in male and female rats." | 3.83 | Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats. ( Kabbaj, M; Sarkar, A, 2016) |
| "Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia." | 2.82 | The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. ( Ceban, F; Ho, R; Jasrai, AK; Kim, H; Lui, LMW; McIntyre, RS; Nasri, F; Nogo, D; Rosenblat, JD; Vinberg, M, 2022) |
| "Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists." | 2.80 | Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. ( Lally, N; Luckenbaugh, DA; Niciu, MJ; Nugent, AC; Roiser, JP; Zarate, CA, 2015) |
| "Ketamine is an anaesthetic medication that acts as an antagonist of the NMDA receptor and has antidepressant potential." | 2.61 | Efficacy of Ketamine in bipolar depression: focus on anhedonia. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, Ł; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczk, A, 2019) |
| "The treatment of major depressive disorder (MDD) is still a challenge." | 1.56 | Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model. ( de Almeida, RF; Elisabetsky, E; Pocharski, CB; Rodrigues, ALS; Souza, DO, 2020) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (37.21) | 24.3611 |
| 2020's | 27 (62.79) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, W | 3 |
| Gu, LM | 2 |
| Sun, CH | 1 |
| Zhou, YL | 2 |
| Wang, CY | 2 |
| Lan, XF | 2 |
| Zhang, B | 3 |
| Ning, YP | 2 |
| Troppoli, TA | 1 |
| Zanos, P | 1 |
| Georgiou, P | 1 |
| Gould, TD | 1 |
| Rudolph, U | 1 |
| Thompson, SM | 1 |
| Becker, B | 1 |
| Nogo, D | 1 |
| Jasrai, AK | 1 |
| Kim, H | 1 |
| Nasri, F | 3 |
| Ceban, F | 2 |
| Lui, LMW | 1 |
| Rosenblat, JD | 4 |
| Vinberg, M | 1 |
| Ho, R | 3 |
| McIntyre, RS | 4 |
| Moraga-Amaro, R | 1 |
| Guerrin, CGJ | 1 |
| Reali Nazario, L | 1 |
| Lima Giacobbo, B | 1 |
| J O Dierckx, RA | 1 |
| Stehberg, J | 1 |
| de Vries, EFJ | 1 |
| Doorduin, J | 1 |
| Klein, ME | 1 |
| Grice, AB | 1 |
| Sheth, S | 1 |
| Go, M | 1 |
| Murrough, JW | 3 |
| Bloomfield-Clagett, B | 1 |
| Ballard, ED | 2 |
| Greenstein, DK | 1 |
| Wilkinson, ST | 1 |
| Grunebaum, MF | 1 |
| Mathew, SJ | 2 |
| Phillips, JL | 1 |
| Fava, M | 1 |
| Sanacora, G | 1 |
| Zarate, CA | 5 |
| García-Baos, A | 1 |
| Gallego-Landin, I | 1 |
| Ferreres-Álvarez, I | 1 |
| Puig-Reyne, X | 1 |
| Castro-Zavala, A | 1 |
| Valverde, O | 1 |
| Martín-Sánchez, A | 1 |
| Gu, L | 1 |
| Zhou, Y | 1 |
| Wang, C | 1 |
| Lan, X | 1 |
| Li, Z | 1 |
| Ning, Y | 1 |
| Belloch, FB | 1 |
| Cortés-Erice, M | 1 |
| Herzog, E | 1 |
| Zhang, XM | 1 |
| Díaz-Perdigon, T | 1 |
| Puerta, E | 1 |
| Tordera, RM | 1 |
| Yang, XH | 1 |
| Jawad, MY | 1 |
| Di Vincenzo, JD | 1 |
| Badulescu, S | 1 |
| Teopiz, KM | 1 |
| Tabassum, A | 1 |
| Mckenzie, A | 1 |
| Meshkat, S | 1 |
| Ho, RC | 1 |
| Singh, B | 2 |
| Vande Voort, JL | 1 |
| Riva-Posse, P | 1 |
| Pazdernik, VM | 1 |
| Frye, MA | 1 |
| Tye, SJ | 1 |
| Kingir, E | 1 |
| Sevinc, C | 1 |
| Unal, G | 1 |
| Johnston, JN | 1 |
| Kadriu, B | 1 |
| Kraus, C | 1 |
| Henter, ID | 1 |
| Olié, E | 1 |
| Lengvenyte, A | 1 |
| Courtet, P | 1 |
| Gałuszko-Węgielnik, M | 1 |
| Wiglusz, MS | 1 |
| Słupski, J | 1 |
| Szałach, Ł | 1 |
| Włodarczk, A | 1 |
| Górska, N | 1 |
| Szarmach, J | 1 |
| Jakuszkowiak-Wojten, K | 1 |
| Wilkowska, A | 1 |
| Cubała, WJ | 1 |
| Rincón-Cortés, M | 1 |
| Grace, AA | 1 |
| Sahib, AK | 1 |
| Loureiro, JRA | 1 |
| Vasavada, MM | 1 |
| Kubicki, A | 1 |
| Joshi, SH | 1 |
| Wang, K | 1 |
| Woods, RP | 1 |
| Congdon, E | 1 |
| Wang, DJJ | 1 |
| Boucher, ML | 1 |
| Espinoza, R | 1 |
| Narr, KL | 1 |
| Yokoyama, R | 1 |
| Higuchi, M | 1 |
| Tanabe, W | 1 |
| Tsukada, S | 1 |
| Naito, M | 1 |
| Yamaguchi, T | 1 |
| Chen, L | 1 |
| Kasai, A | 1 |
| Seiriki, K | 1 |
| Nakazawa, T | 1 |
| Nakagawa, S | 1 |
| Hashimoto, K | 1 |
| Hashimoto, H | 1 |
| Ago, Y | 1 |
| de Almeida, RF | 1 |
| Pocharski, CB | 1 |
| Rodrigues, ALS | 1 |
| Elisabetsky, E | 1 |
| Souza, DO | 1 |
| Rodrigues, NB | 2 |
| Lipsitz, O | 2 |
| Cha, DS | 2 |
| Lee, Y | 2 |
| Gill, H | 2 |
| Majeed, A | 1 |
| Phan, L | 1 |
| Lin, K | 2 |
| Subramaniapillai, M | 2 |
| Kratiuk, K | 2 |
| Mansur, RB | 2 |
| Delfino, RS | 1 |
| Del-Porto, JA | 1 |
| Surjan, J | 1 |
| Magalhães, E | 1 |
| Sant, LCD | 1 |
| Lucchese, AC | 1 |
| Tuena, MA | 1 |
| Nakahira, C | 1 |
| Fava, VAR | 1 |
| Steglich, MS | 1 |
| Barbosa, MG | 1 |
| Sarin, LM | 1 |
| Lacerda, ALT | 1 |
| Wooldridge, LM | 1 |
| Bergman, J | 1 |
| Pizzagalli, DA | 1 |
| Kangas, BD | 1 |
| Siegel, A | 1 |
| Simonson, K | 1 |
| Shekotikhina, M | 1 |
| Chen, MH | 1 |
| Lin, WC | 1 |
| Wu, HJ | 1 |
| Bai, YM | 1 |
| Li, CT | 1 |
| Tsai, SJ | 1 |
| Hong, CJ | 1 |
| Tu, PC | 1 |
| Su, TP | 1 |
| Lins-Silva, DH | 1 |
| Vieira, F | 1 |
| Souza-Marques, B | 1 |
| Jesus-Nunes, AP | 1 |
| Quarantini, LC | 1 |
| Pulcu, E | 1 |
| Guinea, C | 1 |
| Cowen, PJ | 1 |
| Murphy, SE | 1 |
| Harmer, CJ | 1 |
| Wills, K | 1 |
| Lally, N | 3 |
| Richards, EM | 1 |
| Luckenbaugh, DA | 3 |
| Walls, T | 1 |
| Ameli, R | 2 |
| Niciu, MJ | 2 |
| Brutsche, NE | 1 |
| Park, L | 1 |
| Vecchia, DD | 1 |
| Kanazawa, LKS | 1 |
| Wendler, E | 1 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Vital, MABF | 1 |
| Miyoshi, E | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Andreatini, R | 1 |
| Yang, Y | 1 |
| Cui, Y | 1 |
| Sang, K | 1 |
| Dong, Y | 1 |
| Ni, Z | 1 |
| Ma, S | 1 |
| Hu, H | 1 |
| Kim, D | 1 |
| Cheong, E | 1 |
| Shin, HS | 1 |
| Thomas, RK | 1 |
| Baker, G | 1 |
| Lind, J | 1 |
| Dursun, S | 1 |
| Alexander, L | 1 |
| Gaskin, PLR | 1 |
| Sawiak, SJ | 1 |
| Fryer, TD | 1 |
| Hong, YT | 1 |
| Cockcroft, GJ | 1 |
| Clarke, HF | 1 |
| Roberts, AC | 1 |
| Donahue, RJ | 1 |
| Muschamp, JW | 1 |
| Russo, SJ | 1 |
| Nestler, EJ | 1 |
| Carlezon, WA | 1 |
| Parise, EM | 1 |
| Bolaños-Guzmán, CA | 1 |
| Ota, KT | 1 |
| Andres, W | 1 |
| Lewis, DA | 1 |
| Stockmeier, CA | 1 |
| Duman, RS | 1 |
| Nugent, AC | 2 |
| Roiser, JP | 2 |
| DeWilde, KE | 1 |
| Levitch, CF | 1 |
| Iosifescu, DV | 1 |
| Réus, GZ | 1 |
| Carlessi, AS | 1 |
| Titus, SE | 1 |
| Abelaira, HM | 1 |
| Ignácio, ZM | 1 |
| da Luz, JR | 1 |
| Matias, BI | 1 |
| Bruchchen, L | 1 |
| Florentino, D | 1 |
| Vieira, A | 1 |
| Petronilho, F | 1 |
| Quevedo, J | 1 |
| Parsaik, AK | 1 |
| Khosh-Chashm, D | 1 |
| Mascarenhas, SS | 1 |
| Sarkar, A | 1 |
| Kabbaj, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Translational Biomarkers of Fast Acting Therapies in Major Depression[NCT02165449] | Phase 1 | 60 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study[NCT05487885] | Phase 4 | 275 participants (Anticipated) | Interventional | 2022-07-22 | Recruiting | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Randomized, Parallel-group，Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Chinese Patients With Treatment-Resistant Depression.[NCT03887624] | Early Phase 1 | 16 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to Participates could not stand the side effects) | ||
| Ketamine's Actions on Rumination Mechanisms as an Antidepressant[NCT04656886] | 37 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for ketamine and Anhedonia
| Article | Year |
|---|---|
The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits.
Topics: Anhedonia; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Motivation; Reward | 2022 |
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.
Topics: Anhedonia; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2023 |
Ketamine in neuropsychiatric disorders: an update.
Topics: Anhedonia; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Depression; Humans; Ketamine | 2024 |
Efficacy of Ketamine in bipolar depression: focus on anhedonia.
Topics: Anhedonia; Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine | 2019 |
Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Dop | 2020 |
A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings.
Topics: Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Receptors, N-Methyl- | 2022 |
Overcoming Depression by Inhibition of Neural Burst Firing.
Topics: Anhedonia; Animals; Behavior, Animal; Calcium Channels, T-Type; Depressive Disorder; Disease Models, | 2018 |
The promise of ketamine for treatment-resistant depression: current evidence and future directions.
Topics: Anhedonia; Antidepressive Agents; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatm | 2015 |
Efficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis.
Topics: Adult; Anhedonia; Bipolar Disorder; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Mal | 2015 |
5 trials available for ketamine and Anhedonia
| Article | Year |
|---|---|
Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder.
Topics: Administration, Intravenous; Anhedonia; Brain-Derived Neurotrophic Factor; Depressive Disorder, Majo | 2023 |
Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression.
Topics: Adult; Anhedonia; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Rel | 2021 |
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.
Topics: Adult; Anesthetics, Dissociative; Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Majo | 2017 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
Topics: Adult; Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2015 |
29 other studies available for ketamine and Anhedonia
| Article | Year |
|---|---|
Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.
Topics: Anhedonia; Bipolar Disorder; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine | 2022 |
Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit-Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anhedonia; Animals; Benzodiazepines; Femal | 2022 |
Ketamine as a Potential Transdiagnostic Treatment for Anhedonia?
Topics: Anhedonia; Depression; Depressive Disorder, Major; Humans; Ketamine; Reward | 2022 |
A single dose of ketamine cannot prevent protracted stress-induced anhedonia and neuroinflammation in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Carrier Proteins; Corticosterone; Depression; Disease Mod | 2022 |
Pharmacological Treatments for Anhedonia.
Topics: Anhedonia; Brain; Depressive Disorder, Major; Humans; Ketamine; Mood Disorders; Reward | 2022 |
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine.
Topics: Anhedonia; Data Analysis; Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Place | 2022 |
Effects of fast-acting antidepressant drugs on a postpartum depression mice model.
Topics: Anhedonia; Animals; Antidepressive Agents; Depression, Postpartum; Disease Models, Animal; Female; H | 2022 |
Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Mo | 2023 |
Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.
Topics: Anhedonia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; P | 2023 |
Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression.
Topics: Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2023 |
Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress.
Topics: Anhedonia; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Habenula; Ketamine; M | 2023 |
[How can ketamine be used to manage suicidal risk?]
Topics: Anhedonia; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Hum | 2023 |
Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder.
Topics: Adult; Affect; Anhedonia; Apathy; Brain Mapping; Cerebrovascular Circulation; Depressive Disorder, M | 2020 |
(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Mod | 2020 |
Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Mod | 2020 |
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Anhedonia; Bipolar Disorder; Canada; Depressive Disorder, Major; Humans; Ketamine; Retrospect | 2020 |
Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression.
Topics: Anhedonia; Antidepressive Agents; Bipolar Disorder; Humans; Ketamine | 2021 |
Translational Assessments of Reward Responsiveness in the Marmoset.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Callithrix; Excitatory Amino Acid Antag | 2021 |
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation.
Topics: Adult; Anhedonia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2022 |
Letter to the editor about "comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression".
Topics: Anhedonia; Bipolar Disorder; Depressive Disorder; Humans; Ketamine | 2021 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
Topics: Adult; Aged; Anhedonia; Antidepressive Agents; Databases, Factual; Depressive Disorder, Treatment-Re | 2018 |
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex.
Topics: Anhedonia; Animals; Blood Pressure; Callithrix; Citalopram; Conditioning, Classical; Discrimination, | 2019 |
Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice.
Topics: Anhedonia; Animals; Antidepressive Agents; Corpus Striatum; Electric Stimulation; Hypothalamus; Keta | 2014 |
Chronic social defeat and intracranial self-stimulation: unmasking the many faces of depression?
Topics: Anhedonia; Animals; Antidepressive Agents; Corpus Striatum; Hypothalamus; Ketamine; Male; Proto-Onco | 2014 |
BICC1 expression is elevated in depressed subjects and contributes to depressive behavior in rodents.
Topics: Anhedonia; Animals; Behavior, Animal; Case-Control Studies; Dentate Gyrus; Depressive Disorder, Majo | 2015 |
A single dose of S-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain; Catalase; Depressive Disorder; Disease Models, Ani | 2015 |
Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats.
Topics: Anhedonia; Animals; Behavior, Animal; Dendritic Spines; Depression; Disks Large Homolog 4 Protein; E | 2016 |